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and cost savings. Further research is needed to determine the cost-effectiveness 
of ATO+ATRA.
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Objectives: The aim of this study was to compare the costs of disease management 
based on revised diagnoses after centralized histological reviews for sarcoma, GIST, 
and desmoid tumors with the costs based on diagnoses before reviews. MethOds: 
A decision tree was constructed. For both options, the initial pathway was the World 
Health Organization (WHO) Classification of soft tissue and bone tumors. Diagnoses 
were considered concordant only when the final diagnosis was categorized in the 
same manner as the initial finding, as defined by the WHO classification. The deci-
sion tree was evaluated over a time horizon of 12 months. Disease management and 
the probabilities were based on a cohort of patients who had a histological review 
performed within the RRePS (Réseau de Référence en Pathologie des Sarcomes) 
network in 2010. The characteristics of the patient and disease, as well as any rel-
evant guidelines, were used. All of the disease managements were defined by the 
authors of this study. The costs were considered from the French National Health 
Insurance (NHI) perspective and the costs of the histological review were extracted 
from the literature. The costs were assessed for each pathway and expressed in 
Euros 2013. The expected costs were calculated. One-way and probabilistic sensitiv-
ity analyses were performed. Results: A total of 2,425 patients underwent a histo-
logical review. Of these, 341 patients were found to have a discordant diagnosis. Ten 
patients were excluded due to missing data. The costs reached € 8,420 (histological 
review included) when disease management was based on revised diagnoses and 
€ 8,610 when not. cOnclusiOns: In addition to the positive impact of centralized 
histological reviews on the quality of diagnosis for sarcoma, GIST, and desmoid 
tumors, our model demonstrated that histological reviews lower the cost of disease 
management for the French NHI.
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Objectives: A cost analysis investigating TomoTherapy® (Accuray), Elekta 
Volumetric-modulated Arc Therapy (VMAT®) and Varian RapidArc®was conducted 
in patients with head and neck cancer. MethOds: The cost-analysis, funded by 
the National Institute of Cancer (INCa), was performed prospectively based on 
a multicenter study. Cost calculations were strictly based on a micro costing 
approach according to the hospitals’ point of view. Only resources which are likely 
to vary between the strategies being compared were considered. Data on consump-
tion of resources were collected from the treatment planning until the end of the 
last irradiation session. Productivity losses of radiotherapy involved personnel 
related to organisational constraints or absenteeism, costs of administrative per-
sonnel, costs of logistics and general management were not taken into account. 
All costs were given in 2013 euros. Numbers of irradiation sessions were compared 
using Kruskal-Wallis test. Uncertainty was captured by one-way and probabilis-
tic sensitivity analyses using a non-parametric bootstrap method. Results: 174 
patients were enrolled in 16 French centers from February 2010 to February 2012. 
173 economic questionnaires were exploitable. The mean numbers of sessions 
were 34.33 (SD: 2.90) for TomoTherapy® (n= 73) and 34.53 (SD: 2.57) for Varian 
RapidArc® (n= 92, p= 0.603). Eight patients were treated with Elekta Volumetric-
modulated Arc Therapy (VMAT®). For irradiation (all sessions included), the over 
cost of TomoTherapy® (n= 73) reached € 1,109 per patient compared to Varian 
RapidArc® (n= 92). Sensitivity analyses showed that the annual operating time of 
the accelerators played a major role in irradiation costs. cOnclusiOns: This is 
to our knowledge the first study highlighting costs incurred by different Intensity-
Modulated ArcTherapy (IMAT) modalities in this setting. Costs of TomoTherapy® 
appeared more expensive than RapidArc®. The study should be now completed 
by a cost-effectiveness analysis in order to shed further light on which modality 
to focus on.
PCN63
CostEd trEatmENt PatHways of diffusE largE B CEll lymPHoma iN a 
uk PoPulatioN-BasEd CoHort: a PatiENt lEvEl simulatioN modEl
Wang H.I.1, Smith A.1, Roman E.1, Crouch S.1, Jack A.2, Patmore R.3
1University of York, York, UK, 2St James’s University Hospital, Leeds, UK, 3Castle Hill Hospital, 
Hull, UK
Objectives: Diffuse large B-cell lymphoma (DLBCL) is the most common type of 
non-Hodgkin lymphoma and treatment is usually given with curative intent. Using 
restricted datasets derived from clinical trials, previous studies examining the cost 
of treating this cancer have generally focussed on first-line therapy alone; meaning 
of progression-free survival (PFS) curves for dabrafenib and vemurafenib, from their 
respective clinical trials with dacarbazine as a common comparator. The model 
was applied to the conditions of locally-specific population data and treatment 
costs, including adverse events, of patients with MMM. In the model, individuals 
moved from progression-free state to post-progression state or death and were 
followed for 45 weeks. We compared vemurafenib and dabrafenib from the payers’ 
perspective at the price level determined by international reference pricing as of 
December 2013 in terms of costs and progression-free life years (PFLYs). Based on 
the cost-effectiveness model, we carried out budget impact analysis for a scenario 
with vemurafenib only and a scenario with vemurafenib and dabrafenib using their 
projected market shares. Results: Our model has shown that more than 99% of 
total treatment costs of MMM patients in Slovenia were due to drug costs of BRAF 
inhibitors in spite of the fact that treatment of associated adverse events were 5 
times higher in vemurafenib than in dabrafenib, primarily due to higher incidence 
of cutaneous squamous cell carcinoma and keratocanthoma. Treatment with dab-
rafenib vs. vemurafenib allowed to save € 13,009 and gain 0.022 PFLY at a discount 
rate of 3.5%; the sensitivity analysis showed robustness of findings and retained 
dominance of dabrafenib over vemurafenib. Budget impact analysis for a 3-year 
period revealed that introduction of dabrafenib would save the national Sick Fund 
€ 402,000 (€ 5,318,000 in the scenario without dabrafenib vs. € 4,916,000 in the sce-
nario with dabrafenib). cOnclusiOns: Study results suggest that introduction of 
dabrafenib in Slovenia could reduce costs and improve outcomes in MMM.
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Objectives: Multidisciplinary return-to-work (RTW) interventions effectively sup-
port cancer survivors to resume work and potentially increase quality of life, but 
are not or only partly reimbursed by health insurers. To ensure optimal support for 
cancer patients in resuming work, it is essential that hospitals can offer RTW in a 
financially viable way. We analysed the budget impact of a RTW intervention (coun-
selling by occupational physicians + physical exercise) and explored how financing 
of a return-to-work intervention can be arranged. MethOds: The budget impact 
analysis compared costs of RTW support for all patients able and willing to resume 
work versus no standardised support, for a large cancer centre serving a popula-
tion of 1 million inhabitants. Costs and financial benefits relevant from a societal 
perspective were considered, including intervention costs, productivity losses, and 
patients´ costs. We identified which stakeholders, including hospitals, employers, 
health insurances, social security, and patients accrue what costs; and which enjoy 
the financial benefits under different financing arrangements. Results: RTW costs 
are ≈ € 2,000 per patient. For a large cancer centre, the annual budget impact is € 817k 
in 2014, rising to € 14.7m in 2017. Ccosts for patients with a multidisciplinary rehabil-
itation need are typically covered by health insurance, leaving € 735k to be financed 
by the cancer centre. Small improvements in return-to-work and quality of life led 
to substantial reductions in productivity loss and future health care costs. These 
savings outweigh the costs of the intervention, rendering RTW cost-saving from a 
societal perspective. cOnclusiOns: From a societal perspective return-to-work is 
expected to be cost-saving. Hospitals bear the largest share of the cost, while most 
financial benefits fall upon other stakeholders. Re-distributing costs and financial 
benefits among stakeholders would result in feasible financing of the intervention.
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Objectives: To estimate the total costs of arsenic trioxide and all-trans retinoic 
acid (ATO+ATRA) versus ATRA and idarubicin (AIDA) regimens in Italy when used 
in 1st-line APL treatment. ATO+ATRA is approved in 2st-line treatment, but com-
monly used globally in 1st-line. MethOds: A Markov model was developed with 
three health states: non-progressive disease, progressive disease and death. Each 
month, patients could move from non-progressive to progressive disease or die 
from either state. After progression, patients discontinued treatment and switched 
to the other regimen. Treatment regimens, efficacy and adverse events were derived 
from published sources and expert opinion, while each arm’s unit costs (induc-
tion and consolidation for both; maintenance for AIDA only) were collected from 
standard Italian sources. Per-patient costs were reported, and extensive one-way 
sensitivity analyses were conducted. Results: Expected 2-year pharmacy costs 
for ATO+ATRA were € 46,600 versus € 5,300 for AIDA. However, direct medical (DM) 
costs (e.g., monitoring, hospitalizations, etc.) for ATO+ATRA were € 11,300 versus 
€ 28,500 for AIDA. The higher costs stemmed from AIDA consolidation taking place in 
a hospital setting and 2-year maintenance monitoring costs. The treatment failure 
likelihood for patients on AIDA was 14% versus 3% on ATO+ATRA. As these patients 
switched to 2nd-line treatment, relapse costs for AIDA were € 1,500 compared to € 400 
for ATO+ATRA. AIDA patients incurred higher costs from adverse events (AEs) than 
ATO+ATRA (€ 600 vs. € 300, respectively). Results were most sensitive to consolida-
tion cost changes: ATO+ATRA pharmacy costs and AIDA DM costs. cOnclusiOns: 
The results suggest potential cost savings due to DM, progression and AE costs 
for ATO+ATRA, although AIDA pharmacy costs are lower. Additionally, ATO+ATRA 
patients have lower clinical AE risks and shorter treatment duration (8 months 
versus 28 months for AIDA), which could lead to patients’ improved quality of life 
